Ehrenfeld M, Levy M, Sharon P, Rachmilewitz D, Eliakim M
Dig Dis Sci. 1982 Aug;27(8):723-7. doi: 10.1007/BF01393768.
Twelve patients with recurrent polyserositis (RP, familial Mediterranean fever) on colchicine prophylaxis (1.0-2.0 mg daily) for three years or more were evaluated for the presence of gastrointestinal effects possibly attributable to the drug. Two patients had bulky stools, two others had transient diarrhea, and one had heartburn. Serum vitamin B12, calcium, and carotene levels were normal in all cases, and D-xylose absorption was normal in 11 of the 12. Three patients had mild steatorrhea (7.5, 7.9, and 9.9 g daily). Jejunal biopsies from these and a fourth patient with bulky stools but normal fecal fat excretion showed no abnormal histological changes. However, (Na + K)-ATPase activity was significantly decreased in all four cases. Colchicine had to be discontinued in only one of the 12 cases. It is concluded that mild steatorrhea and enzyme inhibition may occur in patients on long-term colchicine prophylaxis and that careful periodic observations for this and other adverse effects is imperative in such patients.
对12例接受秋水仙碱预防性治疗(每日1.0 - 2.0毫克,持续三年或更长时间)的复发性多浆膜炎(RP,家族性地中海热)患者,评估可能归因于该药物的胃肠道影响。两名患者有大便干结,另外两名有短暂腹泻,一名有烧心症状。所有病例的血清维生素B12、钙和胡萝卜素水平均正常,12例中的11例D - 木糖吸收正常。三名患者有轻度脂肪泻(每日7.5、7.9和9.9克)。对这些患者以及第四名大便干结但粪便脂肪排泄正常的患者进行空肠活检,未发现异常组织学变化。然而,这四例患者的(钠 + 钾)-ATP酶活性均显著降低。12例中仅1例不得不停用秋水仙碱。得出结论,长期接受秋水仙碱预防性治疗的患者可能会出现轻度脂肪泻和酶抑制,对此类患者必须定期仔细观察此类及其他不良反应。